

Resource Summary Report

Generated by [NIF](#) on Sep 12, 2026

MHH-NB-11

RRID:CVCL_1412

Type: Cell Line

Proper Citation

RRID:CVCL_1412

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1412

Proper Citation: RRID:CVCL_1412

Description: Cell line MHH-NB-11 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Neuroblastoma

Defining Citation: [PMID:3218965](#), [PMID:11668190](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MHH-NB-11

Synonyms: MHH-NB11, MHHNB11

Cross References: CLO:CLO_0007719, EFO:EFO_0006651, CLDB:cl3479, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:546, BioSample:SAMN03473088, BioSample:SAMN10988427, cancercellines:CVCL_1412, Cell_Model_Passport:SIDM00387, ChEMBL-Cells:ChEMBL3308310, ChEMBL-Targets:ChEMBL2366185, Cosmic:908135, Cosmic:2485948, Cosmic-CLP:908135, DepMap:ACH-000078, DSMZ:ACC-157, DSMZCellDive:ACC-157, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:908135, GEO:GSM887319,

GEO:GSM888395, GEO:GSM1366409, GEO:GSM1670107, GEO:GSM3145573, GEO:GSM3145723, IARC_TP53:21502, LiGeA:CCLE_041, LINCS_LDP:LCL-1975, PharmacDB:MHHNB11_929_2019, PRIDE:PXD030304, Progenetix:CVCL_1412, PubChem_Cell_line:CVCL_1412, Wikidata:Q54905545

ID: CVCL_1412

Record Creation Time: 20220427T220806+0000

Record Last Update: 20260905T181142+0000

Ratings and Alerts

No rating or validation information has been found for MHH-NB-11.

No alerts have been found for MHH-NB-11.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pommerenke C, et al. (2026) Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. iScience, 29(7), 116469.

R??sch L, et al. (2023) ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. Molecular oncology, 17(1), 37.

Durbin AD, et al. (2022) EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma. Cancer discovery, 12(3), 730.

Cai J, et al. (2022) High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. Cell reports, 40(4), 111095.

Morita K, et al. (2020) Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2. Cell, 181(3), 702.